Trillions

Biotech ETFs Vs. The Coronavirus

While much of the stock market has suffered over the past few weeks thanks to fear of the new coronavirus and its global economic fallout, there are a handful of stocks and exchange traded-funds that have managed to avoid damage, and even flourish.On this coronavirus-themed episode of Trillions, Bloomberg Intelligence Senior ETF Analyst Eric Balchunas and Bloomberg Businessweek Editor Joel Weber dive into the world of niche biotech ETFs.Joining them are Paul Yook and Ryan Cinalli of LifeSci Index Partners, who have launched Virtus LifeSci Biotech Product ETF and Virtus LifeSci Biotech Clinical Trials ETF, and are currently working on a third.See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.

Money goes where it's treated best. That simple truth is a big reason why more and more money—trillions, in fact—flows into a powerful, low-cost tool that's quietly transformed investing in recent years. Exchange-traded funds, or ETFs, let you invest in everything from the stock market to gold like never before. This biweekly podcast will demystify them—and delight you in the process.